NRx Pharmaceuticals, Inc.
NRXP
$2.75
$0.124.56%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -35.40% | -30.75% | 38.78% | -3.33% | 4.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.09% | -37.53% | -17.52% | -47.97% | -11.19% |
| Operating Income | 47.09% | 37.53% | 17.52% | 47.97% | 11.19% |
| Income Before Tax | -122.63% | 15.56% | -109.56% | 73.23% | 9.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -122.63% | 15.56% | -109.56% | 73.23% | 9.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -122.63% | 15.56% | -109.56% | 73.23% | 9.41% |
| EBIT | 47.09% | 37.53% | 17.52% | 47.97% | 11.19% |
| EBITDA | 47.10% | 37.54% | 17.53% | 47.98% | 11.19% |
| EPS Basic | -30.57% | 54.45% | -37.76% | 80.01% | 36.93% |
| Normalized Basic EPS | 10.49% | 61.36% | 1.43% | 61.01% | 29.76% |
| EPS Diluted | -30.57% | 54.45% | -37.76% | 80.01% | 37.95% |
| Normalized Diluted EPS | 10.49% | 61.36% | 1.43% | 61.01% | 29.76% |
| Average Basic Shares Outstanding | 70.52% | 85.38% | 51.80% | 33.91% | 43.64% |
| Average Diluted Shares Outstanding | 70.52% | 85.38% | 51.80% | 33.91% | 43.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |